Capitol Vein Blog

Monday, November 19, 2012

Varisolve as a New Varicose Vein Treatment

BTG plc recently issued a press release confirming the clinical benefit of Varisolve (polidocanol endovenous microfoam) to treat varicose veins. Dr. Rosenberg and Dr. McNeill were part of the clinical investigation team participating in this FDA-approved Phase III trial centered in our Frederick, Maryland office. The purpose of the investigation was to find a suitable, effective treatment for varicose veins that does not involve thermal ablation or tumescent anesthesia.

Patients should note that Varisolve is not yet FDA approved for the treatment of varicose veins, as the data just reported at the national American College of Phlebology meeting will be presented to the FDA soon. As soon as the FDA gives approval, Capitol Vein & Laser Centers will be happy to discuss this option with our patients.

Currently the Venefit Procedure (VNUS Closure) is the most durable and effective method to treat reflux in the saphenous vein, the common cause of varicose leg veins. Varicose veins commonly lead to symptoms of leg pain, swelling, throbbing, heaviness, and even restless legs. Treatment is focused on eliminating the backpressure in the leg veins, allowing normal flow to be restored.

As treatment methods continue to evolve, there will likely be several competing options for treating varicose veins, though not all options will be appropriate for each patient. Be sure that you seek advice from a diplomate of the American Board of Phlebology, as doctors with this added competence in venous disease will likely be best informed of the changing landscape in varicose vein care. Dr. Rosenberg and Dr. McNeill, both vascular surgeons with many years of experience, will be glad to answer your questions at any of the Maryland, Virginia or West Virginia offices of Capitol Vein & Laser.


Post a Comment